Document is current
Any future updates will be listed below
-
Authors
Phillips-Beyer, Andrea
Kawata, Ariane K.
Kleinman, Leah https://orcid.org/0000-0002-0632-9689
Kinter, Dalma Seboek
-
Clinical Trials BETA
Clinical trials referenced in this document:
nct03545191 at ClinicalTrials.govDocuments that mention this clinical trial
Number, Duration, and Distribution of Wake Bouts in Patients with Insomnia Disorder: Effect of Daridorexant and Zolpidem
https://doi.org/10.1007/s40263-023-01020-9
What place for daridorexant?
https://doi.org/10.1136/dtb.2023.000037
P4 Daridorexant improves total sleep time (TST) in insomnia patients without altering the proportion of sleep stages
https://doi.org/10.1136/bmjresp-2023-bssconf.15
Meaningful Within-Patient Change on the Insomnia Daytime Symptoms and Impacts Questionnaire (IDSIQ): Analysis of Phase III Clinical Trial Data of Daridorexant
https://doi.org/10.1007/s40290-023-00484-w
Efficacy and Safety of Daridorexant in Older and Younger Adults with Insomnia Disorder: A Secondary Analysis of a Randomised Placebo-Controlled Trial
https://doi.org/10.1007/s40266-022-00977-4
-
Funding
Funding for this research was provided by:
Idorsia Pharmaceuticals
- License Information
-
More Information
Article History
Accepted: 23 May 2023
First Online: 7 June 2023
Declarations
:
: This study was supported by Idorsia Pharmaceuticals Ltd, Allschwil, Switzerland. Idorsia Pharmaceuticals Ltd funded the manuscript writing support (manuscript preparation) and the open access fee.
: Andrea Phillips-Beyer is the director of Innovus Consulting Ltd, which received financial support from Idorsia for work on this study. Ariane K. Kawata and Leah Kleinman are employees of Evidera, which received financial support from Idorsia (via Innovus) for work on this study. Dalma Seboek Kinter is an employee of Idorsia.
: The clinical trial that provided data for this study received ethical approval and was conducted in accordance with the Declaration of Helsinki.
: Participants provided written informed consent.
: Not applicable.
: In addition to Idorsia’s existing clinical trial disclosure activities, the company is committed to implementing the Principles for Responsible Clinical Trial Data Sharing jointly issued by the European Federation of Pharmaceutical Industries and Associations (EFPIA) and the Pharmaceutical Research and Manufacturers of America (PhRMA). Requests for data sharing can be directed to clinical-trials-disclosure@idorsia.com for medical and scientific evaluation. IDSIQ<sup>©</sup> 2020, University of Pittsburgh. All rights reserved. IDSIQ-14 derivative created 2020 by Idorsia Pharmaceuticals Ltd under license and distributed by Idorsia Pharmaceuticals Ltd under license. IDSIQ is further a registered trademark of Idorsia Pharmaceuticals Ltd.
: Not applicable.
: The sponsor and authors were involved in study design, statistical analysis, and interpretation of data. The authors had full access to data and were involved in the critical review and editing of the manuscript for intellectual content. All authors provided approval of the final manuscript prior to submission and agree to be accountable for the work.
